Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): June 26, 2008
VANDA
PHARMACEUTICALS INC.
(Exact
name of Registrant as specified in its charter)
Delaware
(State
or
other jurisdiction of incorporation)
|
|
|
000-51863
|
|
03-0491827
|
(Commission
File No.)
|
|
(IRS
Employer Identification No.)
|
|
|
|
9605
Medical Center Drive
Suite 300
Rockville,
Maryland 20850
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (240)
599-4500
Not
Applicable
|
(Former
Name or Former Address, if Changed Since Last Report)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
o
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
o
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
|
|
|
o
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
On
June
26, 2008, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release announcing
the top-line results from its Phase III clinical trial evaluating tasimelteon
(VEC-162) in patients with chronic insomnia. The full text of this press release
is furnished as Exhibit 99.1 to this Form 8-K. Dr. Mihael H. Polymeropoulos,
M.D., Vanda’s Chief Executive Officer, will discuss these results on a
conference call at 10:00 AM Eastern Time on June 26, 2008.
The
information in Item 7.01 of this Form 8-K and the press release furnished as
Exhibit 99.1 to this Form 8-K shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or
otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
Item
9.01. Financial
Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
|
Description
|
99.1
|
|
Press
Release of Vanda Pharmaceuticals Inc. dated June 26,
2008.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
VANDA
PHARMACEUTICALS INC.
|
|
|
|
By:
|
/s/
STEVEN
A. SHALLCROSS
|
|
|
Name:
Steven A. Shallcross
|
|
|
Title:
Senior Vice President, Chief Financial Officer and
Treasurer
|
Dated:
June 26, 2008